WO2002089856A8 - Techniques and compositions for treating cardiovascular disease by (in vivo) gene delivery - Google Patents

Techniques and compositions for treating cardiovascular disease by (in vivo) gene delivery

Info

Publication number
WO2002089856A8
WO2002089856A8 PCT/US2002/013990 US0213990W WO02089856A8 WO 2002089856 A8 WO2002089856 A8 WO 2002089856A8 US 0213990 W US0213990 W US 0213990W WO 02089856 A8 WO02089856 A8 WO 02089856A8
Authority
WO
WIPO (PCT)
Prior art keywords
cardiovascular disease
vivo
compositions
techniques
gene delivery
Prior art date
Application number
PCT/US2002/013990
Other languages
French (fr)
Other versions
WO2002089856A1 (en
Inventor
H Kirk Hammond
Original Assignee
Univ California
H Kirk Hammond
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, H Kirk Hammond filed Critical Univ California
Priority to AU2002305346A priority Critical patent/AU2002305346A1/en
Publication of WO2002089856A1 publication Critical patent/WO2002089856A1/en
Publication of WO2002089856A8 publication Critical patent/WO2002089856A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

Methods are provided for treating patients with cardiovascular disease, including heart disease and peripheral vascular disease. The preferred methods of the present invention involve in vivo delivery of genes, encoding angiogenic proteins or peptides, to the myocardium or to peripheral ischemic tissue, by introduction of a vector containing the gene into a blood vessel supplying the heart or into a peripheral ischemic tissue.
PCT/US2002/013990 2001-05-03 2002-05-03 Techniques and compositions for treating cardiovascular disease by (in vivo) gene delivery WO2002089856A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002305346A AU2002305346A1 (en) 2001-05-03 2002-05-03 Techniques and compositions for treating cardiovascular disease by (in vivo) gene delivery

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/847,936 2001-05-03
US09/847,936 US20030148968A1 (en) 1995-02-28 2001-05-03 Techniques and compositions for treating cardiovascular disease by in vivo gene delivery

Publications (2)

Publication Number Publication Date
WO2002089856A1 WO2002089856A1 (en) 2002-11-14
WO2002089856A8 true WO2002089856A8 (en) 2004-04-01

Family

ID=25301879

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/013990 WO2002089856A1 (en) 2001-05-03 2002-05-03 Techniques and compositions for treating cardiovascular disease by (in vivo) gene delivery

Country Status (3)

Country Link
US (3) US20030148968A1 (en)
AU (1) AU2002305346A1 (en)
WO (1) WO2002089856A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148968A1 (en) * 1995-02-28 2003-08-07 Hammond H. Kirk Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
EP1121141A2 (en) * 1998-10-13 2001-08-08 Chiron Corporation Angiogenically effective unit dose of fgf and method of administering
US8618052B2 (en) 1998-10-13 2013-12-31 Novartis Vaccines And Diagnostics, Inc. Method of treating coronary artery disease by administering FGF-5
US20100303769A1 (en) * 2000-04-06 2010-12-02 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease
US7166280B2 (en) * 2000-04-06 2007-01-23 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease
ES2288993T3 (en) * 2000-08-17 2008-02-01 Keiya Ozawa DISTRIBUTION OF ANGIOGENIC FACTORS MEDIATED BY ADENOASOCIATED VIRUSES
KR100562824B1 (en) 2002-03-20 2006-03-23 주식회사 바이로메드 Hybrid hepatocyte growth factor gene which has a high expression efficiency and expresses two heterotypes of hepatocyte growth factor
WO2004019946A1 (en) * 2002-08-30 2004-03-11 Mitsubishi Pharma Corporation Inhibitors for excessive accumulation of sodium ion in cells
US7840263B2 (en) 2004-02-27 2010-11-23 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression
US7764995B2 (en) 2004-06-07 2010-07-27 Cardiac Pacemakers, Inc. Method and apparatus to modulate cellular regeneration post myocardial infarct
US7729761B2 (en) * 2004-07-14 2010-06-01 Cardiac Pacemakers, Inc. Method and apparatus for controlled gene or protein delivery
US7981065B2 (en) 2004-12-20 2011-07-19 Cardiac Pacemakers, Inc. Lead electrode incorporating extracellular matrix
US8060219B2 (en) 2004-12-20 2011-11-15 Cardiac Pacemakers, Inc. Epicardial patch including isolated extracellular matrix with pacing electrodes
DE602006017071D1 (en) 2005-01-25 2010-11-04 Five Prime Therapeutics Inc COMPOSITIONS AND METHODS OF TREATING HEART DISEASES
HUE047335T2 (en) * 2005-02-03 2020-04-28 Coda Therapeutics Ltd Anti-connexin 43 compounds for treating chronic wounds
US20070036770A1 (en) * 2005-08-12 2007-02-15 Wagner Darrell O Biologic device for regulation of gene expression and method therefor
US7774057B2 (en) 2005-09-06 2010-08-10 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression for cardiac protection
US20070190028A1 (en) * 2006-02-13 2007-08-16 Jihong Qu Method and apparatus for heat or electromagnetic control of gene expression
KR100742313B1 (en) * 2006-03-21 2007-07-24 퓨리메드 주식회사 New gene and polypeptides of platelet derived growth factor b
US8283441B2 (en) 2006-10-31 2012-10-09 University Of Toledo Na+K+-ATPase-specific peptide inhibitors/activators of SRC and SRC family kinases
CA2669832A1 (en) * 2006-11-15 2008-05-22 Coda Therapeutics, Inc. Improved methods and compositions for wound healing
WO2009085275A2 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polypeptide agent in combination with anti-connexin polynucleotide agent for the treatment of fibrotic conditions
EP2252689A2 (en) * 2007-12-21 2010-11-24 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides for the treatment of surgical adhesions
AU2008343841A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of inhibitors of connexin43 for treatment of fibrotic conditions
JP2011508605A (en) * 2008-01-07 2011-03-17 コーダ セラピューティクス， インコーポレイテッド Wound healing composition and treatment
US20090202606A1 (en) * 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
CA2715765A1 (en) 2008-02-19 2009-08-27 Celladon Corporation Compositions for enhanced uptake of viral vectors in the myocardium
BRPI0911511B8 (en) * 2008-04-09 2021-05-25 Helixmith Co Ltd lyophilized DNA formulation to increase plasmid DNA expression
WO2011034772A1 (en) 2009-09-16 2011-03-24 The University Of Toledo Na/k-atpase ligands, ouabain antagonists, assays and uses thereof
WO2011088210A1 (en) 2010-01-13 2011-07-21 The University Of Toledo Materials and methods related to sodium/potassium adenosine triphosphatase and src
SG11201602452SA (en) 2013-10-22 2016-05-30 Viromed Co Ltd Composition for preventing or treating amyotrophic lateral sclerosis using two or more isoforms of hepatocyte growth factor
CN114010788A (en) 2014-08-22 2022-02-08 奥克兰联合服务有限公司 Channel modulators
JP2020517714A (en) 2017-04-28 2020-06-18 オークランド ユニサービシズ リミテッド Treatment method and new construct
KR102059504B1 (en) 2018-03-22 2019-12-26 한국화학연구원 Agent for targeting heart comprising tannic acid
KR20210027493A (en) 2018-07-19 2021-03-10 주식회사 헬릭스미스 Freeze-dried pharmaceutical composition for naked DNA gene therapy

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672344A (en) * 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5698531A (en) * 1989-03-31 1997-12-16 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5346812A (en) * 1989-09-07 1994-09-13 The University Of Miami Teratogen assay
US5348945A (en) * 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5071962A (en) * 1990-05-31 1991-12-10 The United State Of America As Represented By The Department Of Health And Human Services Nucleotide, deduced amino acid sequence, isolation and purification of heat-shock chlamydial proteins
SE9100612L (en) * 1991-02-06 1992-08-07 Lauzun Corp HYBRID DRIVE SYSTEM FOR MOTOR VEHICLE
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5661133B1 (en) * 1991-11-12 1999-06-01 Univ Michigan Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein
US5586982A (en) * 1992-04-10 1996-12-24 Abela; George S. Cell transfection apparatus and method
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
AU694097B2 (en) * 1992-11-18 1998-07-16 Arch Development Corporation Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle
US5443836A (en) * 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
US5851806A (en) * 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
WO1995034671A1 (en) * 1994-06-10 1995-12-21 Genvec, Inc. Complementary adenoviral vector systems and cell lines
US5652225A (en) * 1994-10-04 1997-07-29 St. Elizabeth's Medical Center Of Boston, Inc. Methods and products for nucleic acid delivery
JP3961019B2 (en) * 1995-02-28 2007-08-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Gene transfer mediated angiogenesis therapy
US20030148968A1 (en) * 1995-02-28 2003-08-07 Hammond H. Kirk Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
US5792453A (en) * 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US5797870A (en) * 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
US5869037A (en) * 1996-06-26 1999-02-09 Cornell Research Foundation, Inc. Adenoviral-mediated gene transfer to adipocytes

Also Published As

Publication number Publication date
US20090082293A1 (en) 2009-03-26
AU2002305346A1 (en) 2002-11-18
US20030148968A1 (en) 2003-08-07
WO2002089856A1 (en) 2002-11-14
US20060286072A1 (en) 2006-12-21

Similar Documents

Publication Publication Date Title
WO2002089856A8 (en) Techniques and compositions for treating cardiovascular disease by (in vivo) gene delivery
WO2002064157A3 (en) Localized myocardial injection method for treating ischemic myocardium
US7297475B2 (en) Medicament injection kit and medicament injection method
EA200200533A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE IN VIVO DELIVERY OF GENES
CA2404163A1 (en) Production of recombinant blood clotting factors in human cell lines
WO1998049300A3 (en) Truncated vegf-related proteins
WO2002004623A3 (en) ANTISENSE COMPOSITIONS TARGETED TO β1 ADRENOCEPTOR-SPECIFIC MRNA AND METHODS OF USE
SI1180121T1 (en) Long lasting insulinotropic peptides
WO2002045431A3 (en) Genetically engineered herpes virus for the treatment of cardiovascular disease
WO2002078439A3 (en) Prevascularized constructs for implantation to provide blood perfusion
EP0837629A4 (en) Pericardial therapeutic and diagnostic agent delivery
AU2001294096A1 (en) Adeno-associated virus-mediated delivery of angiogenic factors
WO1999040197A3 (en) Variants of the angiogenic factor vascular endothelial cell growth factor: vegf
AU5819599A (en) Recombinant adenovirus for tissue specific expression in heart
WO2002043746A3 (en) Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
WO1998050079A3 (en) Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes
NO20060032L (en) Plasmid encoding fibroblast growth factor for the treatment of hypercholesterolemia or diabetes-related angiogenic defects
EA200000828A1 (en) THERAPY OF ANGIOGENESIS WITH THE HELP OF GENE TRANSFER AND METHOD OF INTRA-VASCULAR DELIVERY OF GENES
WO2005047469A3 (en) PORCINE ISOGLOBOSIDE 3 SYNTHASE PROTEIN, cDNA, GENOMIC ORGANIZATION, AND REGULATORY REGION
WO2001032220A1 (en) Gene therapy for diabetic ischemic disease
WO2001054562A3 (en) Apparatus and methods for cardiac surgery
WO2004050844A3 (en) Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
WO2000070665A3 (en) Long lasting anti-angiogenic peptides
WO2002002148A3 (en) Dual recombinant gene therapy compositions and methods of use
WO2003092598A3 (en) Treatment for pompe disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

CFP Corrected version of a pamphlet front page

Free format text: UNDER (54) PUBLISHED TITLE REPLACED BY CORRECT TITLE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP